HN1999000097A - Terapia de combinacion para la fragilidad muscoloesqueletica - Google Patents
Terapia de combinacion para la fragilidad muscoloesqueleticaInfo
- Publication number
- HN1999000097A HN1999000097A HN1999000097A HN1999000097A HN1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A HN 1999000097 A HN1999000097 A HN 1999000097A
- Authority
- HN
- Honduras
- Prior art keywords
- muscoloskeletal
- fragility
- combination therapy
- ghs
- serm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN1999000097A true HN1999000097A (es) | 1999-11-03 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN1999000097A HN1999000097A (es) | 1998-06-16 | 1999-06-15 | Terapia de combinacion para la fragilidad muscoloesqueletica |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (de) |
| JP (1) | JP2002518326A (de) |
| KR (1) | KR20010052852A (de) |
| CN (1) | CN1301160A (de) |
| AP (1) | AP9901582A0 (de) |
| AR (1) | AR018869A1 (de) |
| AU (1) | AU4054799A (de) |
| BG (1) | BG105041A (de) |
| BR (1) | BR9911324A (de) |
| CA (1) | CA2335134A1 (de) |
| CO (1) | CO5070587A1 (de) |
| EA (1) | EA200001186A1 (de) |
| GT (1) | GT199900087A (de) |
| HN (1) | HN1999000097A (de) |
| HR (1) | HRP20000859A2 (de) |
| HU (1) | HUP0102505A3 (de) |
| ID (1) | ID27599A (de) |
| IL (1) | IL138630A0 (de) |
| IS (1) | IS5691A (de) |
| MA (1) | MA26652A1 (de) |
| NO (1) | NO20006312L (de) |
| OA (1) | OA11505A (de) |
| PA (1) | PA8475901A1 (de) |
| PE (1) | PE20000646A1 (de) |
| PL (1) | PL344981A1 (de) |
| SK (1) | SK18912000A3 (de) |
| TN (1) | TNSN99124A1 (de) |
| TR (1) | TR200003544T2 (de) |
| WO (1) | WO1999065486A1 (de) |
| ZA (1) | ZA993975B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| EP1156120B1 (de) | 2000-05-08 | 2006-11-22 | Pfizer Products Inc. | Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors |
| EP1313473A2 (de) * | 2000-08-30 | 2003-05-28 | Pfizer Products Inc. | Arzneizusammensetzungen mit verzögerter wirkstoffabgabe für wachstumshormonsekretionsförderer |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| KR20090107088A (ko) | 2007-02-09 | 2009-10-12 | 트랜자임 파르마 인크 | 거대고리 그렐린 수용체 조절제 및 이의 사용 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/es unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/es not_active Application Discontinuation
- 1999-06-15 AR ARP990102848A patent/AR018869A1/es not_active Application Discontinuation
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/es unknown
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/xx unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-16 EA EA200001186A patent/EA200001186A1/ru unknown
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 CO CO99037622A patent/CO5070587A1/es unknown
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/ja active Pending
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/ko not_active Application Discontinuation
- 1999-06-16 EP EP99923802A patent/EP1087764A1/de not_active Withdrawn
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/hu unknown
- 1999-06-16 CN CN99806237A patent/CN1301160A/zh active Pending
- 1999-06-16 IL IL13863099A patent/IL138630A0/xx unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/sk unknown
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Application Discontinuation
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 ID IDW20002627A patent/ID27599A/id unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/xx not_active Application Discontinuation
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/pt not_active Application Discontinuation
- 1999-06-16 MA MA25628A patent/MA26652A1/fr unknown
- 1999-06-16 GT GT199900087A patent/GT199900087A/es unknown
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/fr unknown
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/xx unknown
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/is unknown
- 2000-12-11 BG BG105041A patent/BG105041A/xx unknown
- 2000-12-12 NO NO20006312A patent/NO20006312L/no not_active Application Discontinuation
- 2000-12-14 HR HR20000859A patent/HRP20000859A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102505A2 (hu) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| ZA993975B (en) | 2000-12-15 |
| PE20000646A1 (es) | 2000-08-05 |
| NO20006312D0 (no) | 2000-12-12 |
| SK18912000A3 (sk) | 2001-10-08 |
| NO20006312L (no) | 2000-12-12 |
| AR018869A1 (es) | 2001-12-12 |
| AU4054799A (en) | 2000-01-05 |
| EA200001186A1 (ru) | 2001-06-25 |
| GT199900087A (es) | 2000-12-07 |
| CO5070587A1 (es) | 2001-08-28 |
| CN1301160A (zh) | 2001-06-27 |
| OA11505A (en) | 2004-05-07 |
| TNSN99124A1 (fr) | 2005-11-10 |
| KR20010052852A (ko) | 2001-06-25 |
| BG105041A (en) | 2001-08-31 |
| BR9911324A (pt) | 2001-04-03 |
| MA26652A1 (fr) | 2004-12-20 |
| TR200003544T2 (tr) | 2001-04-20 |
| CA2335134A1 (en) | 1999-12-23 |
| EP1087764A1 (de) | 2001-04-04 |
| ID27599A (id) | 2001-04-12 |
| JP2002518326A (ja) | 2002-06-25 |
| HUP0102505A3 (en) | 2002-12-28 |
| IS5691A (is) | 2000-10-27 |
| AP9901582A0 (en) | 1999-06-30 |
| PL344981A1 (en) | 2001-11-19 |
| WO1999065486A1 (en) | 1999-12-23 |
| HRP20000859A2 (en) | 2001-04-30 |
| PA8475901A1 (es) | 2000-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2001002264A0 (en) | Sustained release formulations for growth hormone secretagogues. | |
| BR9909903A (pt) | Eficácia máxima de substâncias usadas para melhorar a saúde e bem-estar | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| DE69920689D1 (de) | Vorrichtungen um eine verlängerte medikamententherapie zu erreichen | |
| UY26701A1 (es) | Análogos de tetrahidroisoquinolina útiles como secretagogos de la hormona del crecimiento | |
| PT1143937E (pt) | O e declinio rapido das concentracoes eficazes de droga no plasma formulacoes de libertacao controlada com um arranque rapid | |
| AU2003301190A8 (en) | Administration of capsaicinoids | |
| BR0015188A (pt) | Composições farmacêuticas | |
| HUP0101427A2 (hu) | Pezsgő készítmények | |
| DE69332856D1 (de) | Haarnadelförmiges ribozym | |
| HN1999000097A (es) | Terapia de combinacion para la fragilidad muscoloesqueletica | |
| AR013479A1 (es) | Metodo para aumentar el volumen oseo utilizando agonistas de prostanoide f selectivos no naturales. | |
| IS7065A (is) | Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð | |
| GT199900066A (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea. | |
| HUP0101528A2 (hu) | LHRH antagonisták és antiösztrogének alkalmazása termékenységi rendellenességek kezelésére | |
| ES2136954T3 (es) | Utilizacion de al menos un agua termal de vichy como antagonista de sustancia p. | |
| ES2159357T3 (es) | Derivados terpenoides (sarcodictinas) utiles como agentes antitumorales. | |
| ES2187156T3 (es) | Terapia antidepresiva. | |
| PA8496801A1 (es) | Complejo farmaceutico | |
| MXPA01007952A (es) | Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas. | |
| ES2168562T3 (es) | Medicamentos analgesicos a base de combinaciones con tramadol. | |
| AR034037A1 (es) | Inhibidor de aromatasa en dosis multiples para tratar la infertilidad | |
| UY27920A1 (es) | Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas | |
| AR018321A1 (es) | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación |